Interferon gamma receptor and Tumor necrosis factor receptor (IFNGR and TNFR)

This target entry represents a composite of two distinct cytokine receptor systems: the Interferon-gamma receptor (IFNGR) and the Tumor Necrosis Factor receptors (TNFR1 and TNFR2). These receptors are critically expressed on immune cells (such as T cells, B cells, and macrophages) and within the tumor microenvironment (TME), where they dictate the balance between anti-tumor immunity and pro-tumor inflammation (Source: UniProt P15260, P19438). IFNGR, a heterodimer of IFNGR1 and IFNGR2, mediates the effects of IFN-γ, including MHC upregulation and Th1 differentiation, but can also drive immune evasion by inducing PD-L1 expression on tumor cells. TNFRs mediate the pleiotropic effects of TNF-α, which can induce either cell survival and proliferation via NF-κB or programmed cell death via death domain signaling. In clinical practice, TNF receptors are major targets for treating autoimmune and inflammatory diseases using TNF inhibitors like Adalimumab and Etanercept. IFN-γ signaling is targeted in specific hyper-inflammatory conditions, such as primary hemophagocytic lymphohistiocytosis, using agents like Emapalumab. Because this entry groups multiple independent receptor systems and signaling pathways, it is considered a multi-target description rather than a single canonical molecular entity.

Other names

IFN-gamma receptorTNF-alpha receptorIFNGRTNFRCD119CD120aCD120bTNFRSF1ATNFRSF1B

Therapeutic agents typically function as monoclonal antibodies or soluble decoy receptors that neutralize the ligands (IFN-γ or TNF-α), thereby preventing their binding to IFNGR or TNFR. This blockade inhibits downstream signaling pathways, including the JAK-STAT pathway (for IFN-γ) and the NF-κB or MAPK pathways (for TNF-α), which are critical for mediating inflammatory and immune responses (Source: PubMed PMID: 30333116, 29438515).